Harrow has set September 26 in New York for its Investor & Analyst Day, previewing a full-throated update across its ophthalmic portfolio and pipeline, with live webcast access. The agenda signals deep dives into commercial performance and expansion plans for core brands, including VEVYE in dry eye, IHEEZO in ocular anesthesia, TRIESENCE in the surgical retina setting, and the retina portfolio more broadly, alongside a development spotlight on MELT-300, a sublingual procedural sedation candidate from Melt Pharmaceuticals. The program blends corporate strategy with clinical perspectives from key opinion leaders and includes a dedicated session on patient access and affordability.
This is more than a calendar marker. The event reads as a pivotal positioning move for Harrow as it attempts to convert a collection of acquired assets and compounding capabilities into a coherent, scaled platform in U.S. eye care. The strategic question is whether Harrow can demonstrate durable, cross-portfolio growth levers—spanning chronic front-of-the-eye conditions, high-acuity retina, surgical anesthesia, and biosimilars—at a time when payers are scrutinizing ophthalmic spend and procedural economics are shifting toward ambulatory settings.
Why it matters now is straightforward. Demand in ophthalmology is expanding with aging demographics and rising diabetic retinopathy prevalence, yet category dynamics are tightening. In dry eye, payers are raising the bar for coverage amid a crowded field, which puts a premium on differentiated evidence and frictionless access models for products like VEVYE. In retina, the combination of complex buy-and-bill economics, biosimilar encroachment, and intermittent supply constraints for surgical adjuncts like steroids puts operational execution front and center. Showcasing TRIESENCE expansion and a retina portfolio plan suggests Harrow intends to lean into the specialty distribution and practice economics that define this segment.
MELT-300 could be a swing factor. If a non-injectable, clinic-friendly sedation option can consistently reduce anesthesia staffing and streamline cataract and other outpatient ophthalmic procedures, it opens a tangible cost-of-care and throughput narrative for ambulatory surgery centers. That said, the path from clinical promise to reimbursement reality is fraught: coding, site-of-care budgeting, and responsibility for drug and monitoring costs will determine adoption velocity. Medical Affairs will need to produce pragmatic evidence on workflow, safety, and patient experience to persuade both clinicians and payers.
The event also underscores broader industry currents. Ophthalmology remains a magnet for specialty roll-ups as larger companies prune non-core assets, creating room for focused platforms to accumulate brands and channel strength. Biosimilars are redefining retina economics and clinical behavior, accelerating the need for real-world data to defend or reposition branded portfolios. Compounding-to-branded adjacency, through vehicles like ImprimisRx, offers a differentiated channel but invites regulatory and payer scrutiny. Across all of this, the winners will be those who translate KOL enthusiasm into reproducible, reimbursable practice change backed by outcomes data rather than trial-centric claims.
What to watch coming out of the day: the clarity and evidence behind MELT-300’s value proposition for ASCs; concrete access tactics and gross-to-net discipline for VEVYE; supply reliability and indication breadth for TRIESENCE and how BYQLOVI fits strategically; and the extent to which ImprimisRx becomes a commercial flywheel rather than a parallel business. The core test is whether Harrow can be the acquirer of choice for stranded ophthalmic assets while building a defensible procedural sedation beachhead, or whether reimbursement friction and category crowding cap the growth curve.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
